MOSCOW, Feb. 23, 2021 /PRNewswire/ -- The Russian Direct
Investment Fund (RDIF, Russia's
sovereign wealth fund) announces the delivery of the first batch of
Sputnik V vaccine against coronavirus to Mexico.
On February 3, 2021 the Federal
Commission for the Protection against Sanitary Risk of Mexico (COFEPRIS) approved Sputnik V under the
emergency use authorization procedure without additional clinical
trials in the country. Mexico has
become the first country of North
America to approve Sputnik V.
Sputnik V is approved for use in more than 30 countries making
the vaccine one of the world's top three coronavirus vaccines in
terms of the number of approvals issued by regulatory
authorities.
Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of
Bosnia and Herzegovina),
Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San
Marino and Ghana have
authorized Sputnik V.
Kirill Dmitriev, CEO of the
Russian Direct Investment Fund, commented:
"RDIF supports the efforts of the Government of Mexico to protect the population with a safe
and effective Russian Sputnik V vaccine. Cooperation between
Russia and Mexico on the vaccine is a great example of
pooling efforts to jointly fight the pandemic and save lives. The
positive decision of COFEPRIS to grant an emergency use
authorization to Sputnik V provides people of Mexico with access to one of the best vaccines
in the world."
Sputnik V has a number of key advantages:
- Efficacy of Sputnik V is 91.6% as confirmed by the data
published in the Lancet, one of the world's oldest and most
respected medical journals; It is one of only three vaccines in the
world with efficacy of over 90%; Sputnik V provides full protection
against severe cases of COVID-19.
- The Sputnik V vaccine is based on a proven and well-studied
platform of human adenoviral vectors, which cause the common cold
and have been around for thousands of years.
- Sputnik V uses two different vectors for the two shots in a
course of vaccination, providing immunity with a longer duration
than vaccines using the same delivery mechanism for both
shots.
- The safety, efficacy and lack of negative long-term effects
of adenoviral vaccines have been proven by more than 250 clinical
studies over two decades.
- The developers of the Sputnik V vaccine are working
collaboratively with AstraZeneca on a joint clinical trial to
improve the efficacy of AstraZeneca vaccine.
- There are no strong allergies caused by Sputnik V.
- The price of Sputnik V is less than $10 per shot, making it affordable around the
world.
Russian Direct Investment Fund (RDIF) is
Russia's sovereign wealth fund
established in 2011 to make equity co-investments, primarily in
Russia, alongside reputable
international financial and strategic investors. RDIF acts as a
catalyst for direct investment in the Russian economy. RDIF's
management company is based in Moscow. Currently, RDIF has experience of the
successful joint implementation of more than 80 projects with
foreign partners totaling more than RUB2 tn and covering 95% of the regions of the
Russian Federation. RDIF portfolio
companies employ more than 800,000 people and generate revenues
which equate to more than 6% of Russia's GDP. RDIF has established joint
strategic partnerships with leading international co-investors from
more than 18 countries that total more than $40 bn. Further information can be found at
rdif.ru
Logo:
https://mma.prnewswire.com/media/1140939/Russian_Direct_Investment_Fund_Logo.jpg